Basiliximab or Antithymocyte Globulin for Induction Therapy in Kidney Transplantation: A Meta-analysis

Transplantation Proceedings

Volumn 42, Issue 5, 2010, Pages 1667-1670

  Liu, Y ^a   Zhou, P ^a   Han, M ^a   Xue, C B ^a   Hu, X P ^a   Li, C ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; THYMOCYTE ANTIBODY;

ARTICLE; CLINICAL TRIAL; DEATH; DELAYED GRAFT FUNCTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INCIDENCE; INFECTION; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; META ANALYSIS; NEOPLASM; OUTCOMES RESEARCH; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY TRANSPLANTATION; NEOPLASMS; ODDS RATIO; POSTOPERATIVE COMPLICATIONS; RECOMBINANT FUSION PROTEINS; RISK; TIME FACTORS; TREATMENT OUTCOME;

EID: 77953776257     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2010.02.088     Document Type: Article

References (14)

1. Nashan B. Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs 19 (2005) 39
2. Keown P., Balshaw R., Khorasheh S., et al. Meta-analysis of basiliximab for immunoprophylaxis in renal transplantation. BioDrugs 17 (2003) 271
3. Sollinger H., Kaplan B., Pescovitz M.D., et al. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 72 (2001) 1915
4. Brennan D.C., Daller J.A., and Lake K.D. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 355 (2006) 1967
5. Yang S.L., Wang D., and Wu W.Z. Comparison of single bolus ATG and basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen. Transpl Immunol 18 (2008) 281
6. Heifets M., Saeed M.I., and Parikh M.H. Induction immunosuppression in kidney transplant recipients older than 60 years of age. Safety and efficacy of ATGAM, OKT3 and Simulect. Drugs Aging 21 (2004) 747
7. Clark G., Walsh G., Deshpande P., et al. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation. Nephrol Dial Transplant 17 (2002) 1304
8. Lebranchu Y., Bridoux F., Buchler M., et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2 (2002) 48
9. Kyllönen L.E., Eklund B.H., Pesonen E.J., et al. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Transplantation 84 (2007) 75
10. Mourad G., Rostaing L., Legendre C., et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 78 (2004) 584
11. Tullius S.G., Pratschke J., and Strobelt V. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. Transplant Proc 35 (2003) 2100
12. Al Najjar A., Etienne I., Le Pogamp P., et al. Long-term results of monoclonal anti-IL2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation. Transplant Proc 38 (2006) 2298
13. Watson C.J.E., Bradley J.A., Friend P.J., et al. Alemtuzumab (alemtuzumab 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 5 (2005) 1347
14. Meier-Kriesche H.-U., Arndorfer J.A., Kaplan B., et al. Association of antibody induction with short-and long-term cause-specific mortality in renal transplant recipients. J Am Soc Nephrol 13 (2002) 769